A new, retrospective study trying to tease out the benefits of MitraClip procedures according to the etiology of mitral regurgitation (MR) hints that, compared with conservative management, ...
SAN FRANCISCO, CA (UPDATED)—New, 3-year follow-up data from the COAPT trial provide a solid signal that even after a 2-year delay, patients initially randomized to guideline-directed medical therapy ...
Abbott Laboratories (NYSE:ABT) recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous ...
April 5, 2011 (New Orleans, Louisiana)-Results from the EVEREST IItrial out to two years show that percutaneous repair of the mitral valve with the MitraClip (Abbott) device was significantly less ...
BOSTON -- Contemporary practice had the fourth-generation MitraClip producing low short-term mortality and other good results even in mitral regurgitation (MR) patients previously deemed unsuitable ...
LONDON -- Despite another positive trial, controversy rages on over transcatheter edge-to-edge repair (TEER or M-TEER) in people with symptomatic heart failure (HF) and functional mitral regurgitation ...
NEW ORLEANS — To much acclaim, the COAPT trial demonstrated that use of the MitraClip (Abbott) in a very sick population with symptomatic (heart failure (HF) and secondary mitral regurgitation (MR) ...
Abbott Laboratories ABT recently received the CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair (TMVR) System, MitraClip G4. It is a renowned minimally invasive mitral ...
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Transcatheter mitral valve repair for patients with HF and severe secondary mitral regurgitation ...
Abbott has announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip® System for the ...
Abbott Lifesciences (NYSE:ABT) recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results